CD3 Binding Domains for Bispecific Antibody Stability and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific antibodies, such as those targeting CD3 and CD19, face challenges including high manufacturing costs, laborious production processes, low yields, and stability issues, leading to poor pharmacokinetic profiles and increased risk of cytokine release syndrome (CRS) in cancer immunotherapy.
Innovation Solution
Development of CD3 binding domains and antibodies with enhanced developability profiles and reduced CRS risk, which can be incorporated into various antibody formats, including multispecific and bispecific designs, to improve stability, expression, and targeting specificity while minimizing cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce bispecific antibodies targeting CD3 and CD19, then the antibodies can be manufactured, but the manufacturing costs are high, the production process is laborious, and the yields are low
Solution Approach 1:
The patent divides the antibody molecule into separate domains (CD3-binding domain and CD19-binding domain) that can be independently designed and assembled. This segmentation allows for modular construction of bispecific antibodies, simplifying the manufacturing process and enabling standardized production methods that improve yield while reducing complexity.
Solution Approach 2:
The patent develops a universal platform for producing bispecific antibodies using standardized domain architectures and expression systems. This multi-functional approach allows the same manufacturing framework to produce different bispecific antibodies targeting various antigen pairs, reducing process development time and improving overall productivity across multiple product lines.
2Reliability
If conventional bisspecific antibodies are produced, then they can target cancer cells, but they exhibit stability issues and poor pharmacokinetic profiles
Solution Approach 1:
The patent systematically optimizes critical parameters including domain sequence composition, linker length and sequence, and disulfide bond positioning to enhance antibody stability. These parameter changes result in improved thermal stability, reduced aggregation, and enhanced pharmacokinetic profiles with extended half-life in vivo, directly addressing the stability and duration issues of conventional bispecific antibodies.
3Ease of operation
If anti-CD3 antibodies are used to activate T cells, then T cell activation occurs, but there is an increased risk of cytokine release syndrome
Solution Approach 1:
The patent designs the CD3-binding domain to target specific epitopes on the CD3 complex that preferentially engage cytotoxic T cells (CD8+) over helper T cells (CD4+). This localized targeting approach activates T cells effectively for cancer killing while reducing the recruitment of cytokine-producing CD4+ T cells, thereby lowering the risk of cytokine release syndrome while maintaining ease of T cell activation.
Data Source
AI summary
Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.